SCOTUS’ denial of certiorari in Idenix v Gilead poses especially difficult IP questions for universities and small biotechs

Recent caselaw has raised serious doubts over the enforceability of US genus claims, leaving life sciences innovators in a quandary

Unlock unlimited access to all IAM content